Related references
Note: Only part of the references are listed.Economic costs of diabetes in the US in 2007
Matt Petersen
DIABETES CARE (2008)
Estimating the long-term cost-effectiveness of exenatide in the United States: An adjunctive treatment for type 2 diabetes mellitus
Michael E. Minshall et al.
VALUE IN HEALTH (2008)
Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes
Andrew J. Palmer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Treating diabetes to accepted standards of care: A 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States
ME Minshall et al.
CLINICAL THERAPEUTICS (2005)
The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making
AJ Palmer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model
AJ Palmer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: An application of the CORE Diabetes Model in type 2 diabetes
AJ Palmer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
Validation of the CORE diabetes model against epidemiological and clinical studies
AJ Palmer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients:: An analysis using the CORE Diabetes Model
AJ Palmer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
Diabetesm related utilization and costs for inpatient and outpatient services in the veterans administration
ML Maciejewski et al.
DIABETES CARE (2004)
The direct medical cost of type 2 diabetes
M Brandle et al.
DIABETES CARE (2003)
Trends in lipid management among patients with coronary artery disease
MW Massing et al.
DIABETES CARE (2003)
Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000
JA O'Brien et al.
CLINICAL THERAPEUTICS (2003)
Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers
SI McFarlane et al.
DIABETES CARE (2002)
Lifetime costs of complications resulting from type 2 diabetes in the US
JJ Caro et al.
DIABETES CARE (2002)
Projection of diabetes burden through 2050 - Impact of changing demography and disease prevalence in the US
JP Boyle et al.
DIABETES CARE (2001)
Treatment options for diabetic neuropathic foot ulcers: A cost-effectiveness analysis
J Kantor et al.
DERMATOLOGIC SURGERY (2001)
Potential short-term economic benefits of improved glycemic control - A managed care perspective
J Menzin et al.
DIABETES CARE (2001)